Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5630309 | Journal of Neuroimmunology | 2017 | 10 Pages |
â¢Intrathecal immunoglobulins (Ig) access the main site of inflammation in EAN.â¢Intrathecal Ig ameliorates clinical signs in Lewis rats neuritis model.â¢It reduces autoimmune inflammation, demyelination and complement activation.â¢In a preventive concent at low concentrations it induces a Th2 cytokine shift.â¢Intrathecal Ig could be a novel treatment option for autoimmune neuropathies.
Intravenous human immunoglobulins dominate in the treatment of autoimmune neuropathies. We introduce intrathecal application as a new option for experimental autoimmune neuritis in Lewis rats. After immunisation with neuritogenic P2 peptide, we show a therapeutic and preventive effect of intrathecal human immunoglobulins (5-40Â mg/kg) on clinical and electrophysiological neuritis signs. Histology corroborated a lower degree of inflammation, demyelination, ICAM-1-dependent blood-nerve-barrier permeability and complement activation in the sciatic nerve. After preventive application, immunoglobulins induced a Th2 cytokine shift in the peripheral nerves already before clinical neuritis signs. Intrathecal immunoglobulin application could be a novel immunomodulatory option for autoimmune neuropathies.
Graphical abstractDownload high-res image (211KB)Download full-size image